Objective: There is emerging evidence that angiotensin stimulates adipocyte differentiation and lipogenesis. This study tested the hypothesis that inhibition of angiotensin II by treatment with an angiotensin-converting enzyme inhibitor, perindopril, would reduce fat mass in rats. Design: After a 12-day baseline, rats were divided into two groups: one was untreated and the other received perindopril (1.2 mg kg À1 per day) in drinking water for 26 days. Subjects: In total, 16 male Sprague-Dawley rats aged 10 weeks at the start of the study. Measurements: Plasma leptin was measured in samples collected at baseline, half-way through and at the end of treatment. Body weight, food and water intake were measured daily throughout the experiment. Body fat mass, bone and lean mass were determined by dual energy X-ray absorptiometry (DEXA) at the end of the treatment period. Results: Daily food intake was the same in both groups throughout the study. By the end of treatment, animals receiving perindopril showed a modest reduction in weight gain relative to the untreated animals (62.4 ± 5.0 g vs 73.0 ± 4.0 g; Po0.05). DEXA analysis showed that body composition was greatly altered and the perindopril-treated group had 26% less body fat mass than the untreated group (61.0 ± 5.2 g vs 44.4 ± 4.2 g; Po0.01). The reduction in body fat mass was correlated with reductions in the weight of both the epididymal and retroperitoneal fat pads (Po0.001). Similarly, plasma leptin was reduced by perindopril treatment (4.64 ± 0.56 ng ml À1 ) compared to the untreated group (8.27 ± 1.03 ng ml À1 ; Po0.001). In contrast, there were no differences in lean or bone mass between the two groups. Conclusion: Oral treatment with perindopril selectively reduced body fat mass without influencing daily food intake. In contrast, there were no differences in lean or bone mass between the two groups.
Introduction
Changes in lifestyle and diet are factors that have lead to a rapid increase in the incidence of overweight and obesity worldwide. The development of obesity is related to a mismatch between energy requirements and energy intake in food, resulting in the storage of excess energy as triglycerides in adipose tissue. In the last decade, there has been increasing recognition that adipose tissue is not only a passive store of triglycerides, but also an endocrine organ that secretes many hormones that regulate metabolic function and influence adipocyte growth. 1 Components of the renin-angiotensin system (RAS) have been detected in adipose tissue, 2, 3 with pluripotent local and systemic effects. 4 Studies have illustrated proportionate associations between plasma angiotensinogen (AGT) levels, [5] [6] [7] plasma renin activity 8 and plasma angiotensin-converting enzyme (ACE) activity 6 with body mass index (BMI) in humans. Supporting this was a positive correlation between AGT expression and subcutaneous 9, 10 and visceral adipose tissue mass 10, 11 in obese humans.
Recent work has revealed many effects of the RAS on growth and metabolism in adipose tissue. Angiotensin II (Ang II), the major bioactive peptide of the RAS, signals the recruitment of new adipocytes from preadipocytes 4 in adipose tissue and mesenchymal stem cells. 12 Thus, Ang II from mature adipocytes may induce preadipocyte maturation in a paracrine manner. 13 Furthermore, Ang II plays an important role in enlarging mature human adipocytes by increasing triglyceride content. 14, 15 Other actions of Ang II, such as vasoconstriction, also apply to adipose tissue. Reduced circulation to adipose tissue by vasoconstriction leads to the accumulation of free fatty acids 16, 17 and a reduction in lipolysis. 13 In addition, Blaak et al. 16 found that basal abdominal subcutaneous adipose tissue blood flow per unit fat mass was profoundly lower in obese compared to slim subjects. Therefore, it was proposed that obese individuals have elevated levels of Ang II that may lower adipose tissue blood flow to the extent that lipolysis is impeded, resulting in increased adiposity. 13 More recently, these investigators also showed that when adipose tissue samples from lean and obese subjects were then subjected to treatment with Ang II in culture, the basal rate of lipolysis was inhibited. These reductions in lipolysis were inhibited by treatment of the cells with an AT 1 receptor antagonist. 18 Taken together, the research at the cellular and tissue level provides evidence that Ang II increases body adiposity by (1) stimulating precursor cell differentiation, (2) increasing lipid content of mature fat cells, (3) inhibiting lipolysis in adipose tissue by reducing tissue perfusion and (4) inhibiting lipolysis directly in cells by an AT 1 receptor-dependent mechanism. These data indicate that systemic blockade of the RAS should also reduce fat mass and body weight in experimental subjects and conversely, increasing Ang II should increase these parameters. However, the evidence from studies in animals and humans has been equivocal.
A selection of key studies is summarized in Table 1 . In general, studies in rats showed that blockade of the RAS with an AT 1 receptor antagonist reduces body weight gain and visceral or epididymal fat mass. [19] [20] [21] This effect is usually accompanied by a reduction in food intake, and some studies also suggest that increases in fatty acid metabolism or energy expenditure might be part of the mechanism. However, some AT 1 receptor antagonists were more effective than others, 21 and this difference was attributed to the additional property of some drugs in this class, which are partial agonists at peroxisome proliferator-activated receptor (PPAR)-g. 22 In humans, trials of AT 1 receptor antagonists with low numbers of subjects did not produced significant weight loss, 18, 23 but one study reported a significant reduction in visceral fat. 23 Blockade of the RAS by selective deletion of the gene for the angiotensin precursor, AGT, caused a large reduction in body weight and fat mass without altering food appetite in mice. 24 In comparison, rats with a selective reduction in brain AGT showed an increase in appetite, yet also lost body weight and fat mass. 25 Thus, blockade of the RAS reduces weight gain and fat mass, but the mechanism may be independent of food intake depending on the whether the brain RAS is targeted in addition to systemic blockade. 28 These effects in the triplecopy ACE mice could not be blocked by an AT 1 antagonist.
The inconsistent results in animals suggest it is important to distinguish the effects of angiotensin blockade from PPAR-g agonism, body weight from body fat mass and define the effect on food intake. We hypothesized that inhibition of Ang II would reduce body weight gain by selective inhibition of adipose tissue growth. Our aim in this study was to treat rats with the ACE inhibitor perindopril and determine the effect on fat mass in relation to food intake and body weight during a 26-day treatment period. The use of perindopril avoided the possible complication of the partial PPAR-g agonism associated with some of the AT1-receptor antagonists. We used dual-energy X-ray absorptiometry (DEXA) analysis of body composition to measure fat, skeletal and lean mass separately and weighed epididymal and retroperitoneal fat pads directly. We also measured leptin before and during treatment as the plasma levels of this adipocytokine correlate highly with body adiposity in rodents 29 and humans.
30,31

Materials and methods
Animals
The Animal Ethics Committee of the Howard Florey Institute approved all methods used in this experiment. Male Sprague-Dawley rats were housed in boxes allowing individual measurement of food and water intake. Animals were exposed to 12 h of alternating light (0700-1900 hours) and dark (1900-0700 hours). A baseline period (no treatment, 12 days) preceded the experimental period (26 days). Daily measurements of body weight, food and water intake were taken for the entire course of the experiment.
At the start of the study, the rats were 10 weeks old and had a mean weight of 280 ± 15 g (n ¼ 16). After the baseline phase (day 13), they were divided into two groups of equal mean body weight. Both groups received food (standard rat chow, Barastoc GR2, Ridley Agriproducts Pty. Ltd., Victoria, Australia) and water ad libitum for the duration of the study. One group (n ¼ 8) received the ACE inhibitor, perindopril in the drinking water, whereas the other group remained untreated. Perindopril powder was the kind gift of Servier Australia.
Blood samples (0.5 ml) were collected with heparincontaining (David Bull Laboratories, Victoria, Australia) syringes from the tail vein of restrained rats that were warmed under a heat lamp on days 12, 25 and 38, which was immediately before, half-way through and at the end of the treatment phase, respectively. The blood was centrifuged (4 1C, 3200 r.p.m., 10 min). The haematocrit was measured and the plasma was frozen at À20 1C until subsequent analysis of leptin.
Tissue collection
On completion of the experiments, the rats were anaesthetized using pentobarbitone sodium (Nembutal 60 mg kg À1 , i.p.; Boehringer Ingelheim, New South Wales, Australia). Rats were then killed by cardiac puncture and epididymal and retroperitoneal fat pads were dissected and weighed.
Leptin measurement
The method for measuring plasma leptin has been described in detail previously. 32 It is based on a commercially available radioimmunoassay kit (Linco Research, St Charles, MO, USA), using rat leptin for the standards (0.5-50 ng ml
À1
). After addition of rat leptin polyclonal antibody to plasma samples, the standards and samples were incubated overnight at room temperature.
125 I-Leptin (tracer) was added the following day and overnight incubation was repeated. The next day, cold precipitating reagent was added (1.0 ml; antiguinea-pig immunoglobulin G, raised in goats) and incubated (20 min, 4 1C) for precipitation of the leptin-antibody complex. All samples were centrifuged (3000 r.p.m., 20 min, 4 1C, RT7, Sorvall Instruments, MN, USA) to separate the bound fraction, which was counted for 10 min in a g-counter (Cobra II Autogamma, Packard Instruments, CT, USA).
Dual energy X-ray absorptiometry DEXA is an accurate noninvasive technique of body composition analysis. It allows rapid and precise examination of in vivo body adiposity. Furthermore, DEXA produces specific measurements of bone mineral content, lean mass and percentage fat. 33 DEXA measurement was conducted using a fan-beam X-ray machine (QDR Hologic model 4500, MA, USA) with multi-element solid-state detectors. The DEXA software used was optimized for adult rats weighing 200-750 g. During analysis, animals were anaesthetized (ketamine 100 mg kg À1 and xylazine 20 mg kg À1 i.p.) and positioned prone, parallel to the long axis of the scanning table surface. A whole body scan was then performed to measure body weight, bone mineral content, body fat and lean mass and percentage fat. Body weight measured by DEXA is the sum of lean mass, fat and bone mineral content.
Statistics
Results are expressed as mean±s.e.m. After the baseline period, changes in body weight, food and water intake were analysed based on the last day of the baseline period. 
Results
Food and water intake Food intake during the baseline period was similar in both groups and remained virtually identical throughout the treatment period (Figure 1a) . Water intake during the baseline period was comparable in both groups (35-42 ml per day) (Figure 1b) . During the experimental period the untreated group drank 35-40 ml per day). Perindopril treatment caused the animals to increase water intake to 54-82 ml per day (Po0.001). This represented a 110% increase from the average daily intake in this group during the baseline period (Po0.001).
Body weight
Both groups of animals were of the same body weight at the start of the experiment (280 ± 15 g). Body weight remained very similar in the two groups until the end of treatment (Figure 1c) , when there was a small reduction (B10 g or 2.4% of body weight) compared to the untreated group (NS). Overall weight gain was significantly reduced in the perindopril-treated group compared to the untreated group (62.4 ± 5.0 g vs 73.0 ± 4.0 g; Po0.05).
Epididymal and retroperitoneal fat mass Epididymal fat mass in the perindopril-treated group (4.64 ± 0.42 g) was less than that of the untreated group (6.62±0.56 g, Po0.01). Similarly, retroperitoneal mass in the perindopril-treated group was less than in the untreated group (3.45 ± 0.42 g and 2.41 ± 0.20 g, respectively, Po0.05).
Leptin and haematocrit analysis Blood samples were collected at the end of the baseline period and at the midpoint (13 days) and end (26 days) of the treatment period. During the baseline stage, plasma leptin levels were similar in both groups (untreated 4.16± 0.71 ng ml
À1
; perindopril-treated 4.22 ± 0.8 ng ml
). At the midpoint of the treatment period, leptin levels remained similar in both groups (Figure 2) . By the end of the treatment period, the perindopril-treated rats had significantly less circulating leptin (4.64 ± 0.56 ng ml
; Po0.001) compared to the untreated rats (8.27 ± 1.03 ng ml
).
The haematocrit of the blood samples collected at these times was not different between the groups and remained unchanged over the course of the study (ranging between 41 and 44%).
DEXA analysis of body composition and weight DEXA analysis was conducted in all animals at the end of the treatment phase. Body weights of the perindopril-treated and untreated groups calculated by DEXA were 420.8±7.4 and 432.6±11.4 g, respectively (Figure 3a) . Lean mass was not significantly different between the two groups, measuring 365.7 ± 8.3 g in the perindopril-treated and 360.7 ± and perindopril-treated (closed circles) groups of Sprague-Dawley rats. After a 12-day baseline period, rats were divided into the two groups (n ¼ 8 per group). The treated group received perindopril (1.2 mg per day) for 26 days (indicated by horizontal line). Food intake was unchanged, whereas water intake was increased in the perindopril-treated group. Body weight was not significantly reduced by treatment with perindopril.
ACE inhibition selectively reduces body fat mass ML Mathai et al 11.9 g, respectively ( Figure 3 ). Bone mineral content was also unchanged, measuring 10.9 ± 0.2 g in the perindopril-treated group and 11.3 ± 0.3 g in the untreated group. In contrast, total body fat was 26% less in the perindopril-treated group, measuring group 44.4 ± 4.2 g compared with 61.0 ± 5.2 g (Po0.01) in the untreated group (Figure 3c ). There was very high correlation between the plasma concentration of the adipocytokine leptin and total body fat mass and epididymal and retroperitoneal fat pads (Figures 4a-c ; r-value ¼ 0.87-0.93, Po0.001). There was also a high correlation between the retroperitoneal, epididymal and total body fat mass high correlation (Figures 4d-f ; r-value ¼ 0.79-0.84, Po0.001).
Discussion
The major finding of this study is that treatment with perindopril induced a large reduction in fat mass without reducing food intake. By the end of the treatment period, all experimental measures of adiposity, namely, plasma leptin levels, epididymal and retroperitoneal fat pad mass and total body fat mass were uniformly decreased in the perindopriltreated group compared to the untreated group. These data are strongly supportive of a role for angiotensin in the growth of adipose tissue.
In contrast to the reduction in body fat, measures of lean mass were unchanged or even slightly increased. Thus, the treatment did not retard musculoskeletal growth in the rats. The selective inhibition of adipose tissue growth also explained the small reduction in overall body weight, as fat ACE inhibition selectively reduces body fat mass ML Mathai et al mass was only a small proportion of total mass at this age (B14% in the untreated animals). By the end of the study, plasma leptin had doubled in the untreated group, reflecting the increases in total body and individual fat pad mass relative to the perindopril-treated group. The increase in leptin did not alter result in a reduction in appetite, which is a common finding in obese humans and rodents and is thought to be due to the development of leptin insensitivity. 34 In contrast to the lack of change in food intake, it was evident that perindopril treatment stimulated water intake (Figure 1b) . This effect of a low systemic dose of perindopril has been noted previously and is attributed to an increased formation of Ang II in the lamina terminalis of the brain, which responds to Ang II by stimulating drinking. between total body fat mass (measured by dual energy X-ray absorptiometry (DEXA) scan) and individual fat pad mass with plasma leptin (a-c). Similarly, body fat mass was strongly correlated with both epididymal fat pad mass (d) and retroperitoneal fat pad mass (e), as were the fat pads to each other (f).
ACE inhibition selectively reduces body fat mass ML Mathai et al bloodstream which perfuses areas of the lamina terminalis of the brain which do not have a blood-brain barrier. 36 It is proposed that due to the high concentration of the enzyme in this area, 36 the activity of ACE is not effectively blocked by this dose of perindopril, allowing local conversion of Ang I to II and potent stimulation of drinking. 37 It has also been noted that rats treated long term with an AT-1 receptor antagonist have increased urinary volume and increased water intake. 38 Thus, the increase in water intake may be secondary to increased urine loss as opposed to a primary hyperdipsia mediated by the action of angiotensin in the brain.
Mechanisms underlying the reduction in fat mass
We attribute the changes in body weight to a reduction in circulating and tissue angiotensin mediated by oral intake of the ACE inhibitor perindopril. Although we did not directly measure angiotensin, it has been established previously that this dose of perindopril is effective in reducing the elevated plasma and tissue levels of angiotensin in the (mRen-2)27 transgenic rat. 39 In the last 2 days of the treatment period, the average body weight gain of animals in the unrestrictedperindopril group was less than that of the untreated group (Figure 1 ), reflecting the reduction in fat mass. In addition, epididymal fat mass, total body fat mass and plasma leptin levels ( Figure 3 ) in the perindopril-treated group were significantly reduced compared to the untreated group. The DEXA measurements were consistent with other measures of body weight and fat mass. For body weight, there was a 0.98 correlation between electronic balance ( Figure 1 ) measurements compared to that calculated by DEXA analysis (Figure 3 ). There were also high correlations between the weights of the retroperitoneal and epididymal fat pads. As expected, the values for the untreated rats generally occupied the heavier end of the range and those of the perindopril-treated animals were grouped at the lighter end. These strong correlations demonstrate the effectiveness of DEXA as a method of determining body composition. Total body fat measured by the scan was proportional to the mass of the epididymal and retroperitoneal fat pads, as well as the plasma concentration of leptin. The increase in leptin with fat mass is thought to be due to a constant expression of leptin in adipose tissue. This study replicates the general finding that the effect of increased leptin in reducing food intake is reduced or lost in obese animals and with ageing. 34, 40 Several studies have implicated a phosphatase enzyme that dephosphorylates the initial kinase in the leptin signal transduction pathway, causing the loss of leptin signalling on appetite control in the hypothalamus. Mice with a neuronal deletion of phosphotyrosine phosphatase 1B (PTP-1B) exhibit improved responses to exogenous leptin and resistance to diet-induced obesity. It has been shown that an increased expression of phosphotyrosine phosphatase 1b in rats transitioning from youth to middle age (8-20 weeks) reduces intracellular signalling in hypothalamic neurones in response to leptin. 40 This age range is close to that of the rats in our study (10-16 weeks) , and it is possible that the emergence of leptin resistance in appetite control is related to an increased expression of PTP-1B in the hypothalamus. The results of this study on fat mass and body weight are interesting when compared with a number of recent publications that have also studied the effects of ACE inhibition in rats over a range of ages. Two very recent studies 41, 42 have shown that body weight and fat mass are reduced when ACE treatment started at a young age (birth and 6 weeks, respectively) in rats. Both these studies also reported that food intake was reduced (in contrast to our present study). The effects were observed within a short period of 6 and 4 weeks of treatment, in line with our study. In contrast, a study with older rats (24 months old) reported smaller reductions in body fat composition and treatment of 24 weeks was much longer. 43 When considering these studies, it seems likely that the effect of ACE inhibition on body weight and appetite may be influence by age, with younger animals being more sensitive to the treatments and reducing appetite as well as body fat mass in a shorter treatment period. There may also be a dose-related effect on appetite, as the dose used in this study (1.2 mg kg À1 per day)
was the lowest of any of the studies and did not influence appetite. This lack of effect on food intake has also been observed in several animal models that have a genetically engineered reduction in angiotensin. AGT-knockout, 24 ASRAogen rats 25 and our own studies with ACE-knockout mice 44 all show a reduction in fat mass and body weight gain without reducing food intake. The results of this study on body weight gain are consistent with recent reports in rats treated with angiotensin AT 1 per day) also reduced epididymal fat mass. 19, 21 Food intake was reduced in both these studies, which could have accounted for the lower body weight and fat mass ( Table 1) . The investigators also measured increases in other mechanisms of reducing fat mass, showing that AT 1 receptor inhibition increased whole body energy utilization 21 and the plasma concentration of the adipocytokine, adiponectin, which enhances fatty acid metabolism. 45 There was also a difference in outcome depending on the AT 1 antagonist used, where valsartan was found to be less effective than telmisartan in reducing fat mass. 21 The authors proposed that this difference could be due to the additional partial PPAR-g agonist property of telmisartan. Recently, several studies have investigated AT 1 receptor antagonists with regard to their additional agonist action on PPAR-g receptors. 22, 46 Telmisartan, losartan, irbesartan and candesartan have been shown to have more PPAR-g agonist properties, whereas valsartan appears to have little. It has been suggested that the effects of the sartan-class of nonpeptide angiotensin receptor antagonists on food intake, adiponectin secretion and adipocyte differentiation may vary ACE inhibition selectively reduces body fat mass ML Mathai et al according to their PPAR-g agonism. Hence, the reduced effects of valsartan relative to telmisartan on body weight reduction might be explained by the low PPAR-g agonist properties of valsartan. 21 As we used an ACE-inhibitor (with no reported PPAR-g agonist property) and also observed a reduction in fat mass, our findings support a direct effect of angiotensin blockade on fat reduction, which is independent of any mechanism mediated by PPAR-g receptors. Clinically, drugs that are pure PPAR-g agonists such as the glitazones are used to improve insulin sensitivity. They also promote adipocyte differentiation and weight gain is a common side-effect of their use. This effect was specifically tested in a recent study that investigated the effect of telmisartan on glitazone-induced weight gain in two models of obesity. 20 They showed that both obese Zucker rats and high-fat fed Sprague-Dawley rats gained more weight when treated with the PPAR-agonist pioglitazone, and that the increases in abdominal and total body fat were substantially decreased by concomitant treatment with telmisartan. This effect of telmisartan was mediated by reduced food intake as pair-fed animals showed a similar reduction in fat mass as animals treated with both pioglitazone and telmisartan. This is a different result to our study, where perindopril did not alter appetite. Thus, further investigation is required to determine the different effects of angiotensin antagonist drugs on mechanisms that reduce fat mass.
Clinical perspective
In humans, earlier studies noted that a reduction in body weight often occurred during treatment with ACE inhibitors. 47, 48 More recent studies on the effect of treatment with angiotensin antagonists on body weight have been equivocal. A study in obese and lean subjects using the AT 1 inhibitor irbesartan had no effect on body weight or whole body energy utilization. 18 This may be due to the relatively low dose (150 mg per day, that is, o2 mg kg À1 per day) or short duration of treatment (2 weeks) in this study. Another study used telmisartan (20-40 mg per day) for 24 weeks and showed that, while body weight was not reduced, visceral fat (measured by computed tomography scan) was reduced whereas subcutaneous fat was unchanged. 23 We observed that the reduction in body weight gain in the perindopriltreated group only became significant after 4 weeks. However, the reduction in fat mass in the rats was relatively large, so we speculate that this would have been measurable (by DEXA imaging) at an earlier stage than the reduction in body weight gain. There is evidence that caloric reduction either by a low calorie diet þ pancreatic lipase inhibition (Orlistat) or gastric lap-banding, reduces body weight in a ratio of 1:5.5 (lean:fat) and 1:5.9, respectively. 49 Our study, which showed a selective reduction of fat mass and a trend towards an increased proportion of lean mass, without reducing food intake, suggests that ACE inhibition reduces fat mass via a different mechanism to weight loss techniques that act primarily through the inhibition of caloric intake.
In summary, oral treatment of Sprague-Dawley rats with perindopril selectively reduced body fat mass while sparing lean mass and bone mineral content. The change in body composition was not associated with any reduction in food intake. The mechanism of the reduction in fat mass has not yet been determined, but the data is consistent with evidence in the literature for the role of angiotensin in promoting adipocyte differentiation and lipogenesis and conversely, the effects of angiotensin antagonists that increase metabolic rate and adiponectin secretion.
